DexCom (NASDAQ:DXCM) Director Nicholas Augustinos Sells 6,539 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) Director Nicholas Augustinos sold 6,539 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $84.04, for a total transaction of $549,537.56. Following the sale, the director owned 29,293 shares in the company, valued at $2,461,783.72. The trade was a 18.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nicholas Augustinos also recently made the following trade(s):

• On Monday, September 14th, Nicholas Augustinos sold 1,550 shares of DexCom stock. The shares were sold at an average price of $84.02, for a total transaction of $130,231.00.

DexCom Trading Up 1.0%

Shares of DXCM stock opened at $87.34 on Thursday. The company’s fifty day simple moving average is $83.52 and its two-hundred day simple moving average is $73.07. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $92.59. The stock has a market capitalization of $32.96 billion, a price-to-earnings ratio of 34.52, a PEG ratio of 1.45 and a beta of 1.42.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same period last year, the company earned $0.48 earnings per share. As a group, analysts anticipate that DexCom, Inc. will post 2.64 earnings per share for the current year.

Hedge Funds Weigh In On DexCom

Institutional investors have recently added to or reduced their stakes in the business. Norges Bank purchased a new position in DexCom in the 4th quarter worth approximately $483,356,000. Legal & General Group Plc purchased a new stake in shares of DexCom during the 2nd quarter valued at $173,237,000. Deutsche Bank AG bought a new stake in shares of DexCom during the 2nd quarter worth $164,035,000. Employees Provident Fund Board bought a new stake in shares of DexCom during the 4th quarter worth $145,352,000. Finally, J. Stern & Co. LLP grew its position in DexCom by 2,114.8% in the fourth quarter. J. Stern & Co. LLP now owns 1,601,973 shares of the medical device company’s stock worth $106,323,000 after acquiring an additional 1,529,641 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. lifted their target price on DexCom from $65.00 to $82.00 and gave the company a “neutral” rating in a report on Friday, July 31st. Wells Fargo & Company increased their price target on shares of DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Weiss Ratings upgraded shares of DexCom from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Benchmark boosted their price objective on shares of DexCom from $77.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Finally, Stifel Nicolaus set a $95.00 target price on shares of DexCom and gave the stock a “buy” rating in a report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $88.71.

Key Stories Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Expanded leadership role: CFO Jereme Sylvain will also serve as chief operating officer, potentially improving coordination between DexCom’s financial and operational functions as the company expands its continuous glucose-monitoring business. DexCom CFO Jereme Sylvain to Take Additional Role of COO
• Positive Sentiment: Strong recent financial results: DexCom’s latest quarterly report exceeded expectations, with earnings per share of $0.70 versus the $0.61 consensus estimate and revenue of $1.31 billion versus $1.29 billion expected. Revenue increased 13.1% year over year, supporting the growth outlook for its G7 and other CGM products.
• Positive Sentiment: Generally favorable analyst view: The stock carries a “Moderate Buy” consensus rating, with recent bullish targets including $95 from Stifel, $96 from UBS and $105 from Robert W. Baird. The average published target is $88.71, suggesting relatively limited but still positive upside based on the cited estimates.
• Neutral Sentiment: Insider selling appears scheduled: EVP Michael Brown sold 1,700 shares, while Director Nicholas Augustinos sold a combined 8,089 shares. Because the transactions were conducted under pre-arranged trading plans, they may reflect routine diversification rather than a negative view of DexCom’s prospects. DexCom insider transaction filing
• Negative Sentiment: Multiple insider sales could weigh on sentiment: The recent sales, including EVP Jereme Sylvain’s disposal of 3,638 shares for approximately $303,000, add a short-term cautionary signal even though the executives retained substantial holdings. DexCom insider selling report

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.